EP Patent

EP3971167A1 — Formulations of enzalutamide

Assigned to Astellas Pharma Inc · Expires 2022-03-23 · 4y expired

What this patent protects

This disclosure provides formulations of enzalutamide and their use for treating hyperproliferative disorders.

USPTO Abstract

This disclosure provides formulations of enzalutamide and their use for treating hyperproliferative disorders.

Drugs covered by this patent

Patent Metadata

Patent number
EP3971167A1
Jurisdiction
EP
Classification
—
Expires
2022-03-23
Drug substance claim
No
Drug product claim
No
Assignee
Astellas Pharma Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.